SNYNF
SanofiPrice
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R Apr 23 Sanofi reported strong Q1 2026 results with 13.6% sales growth and 1…
- R Apr 27 Sanofi's 6-K filing reports multiple regulatory catalysts: FDA appro…
- R Jun 8 Sanofi announced FDA priority review for venglustat NDA to treat typ…
- X Jul 31 Short interest falls 59.9% to 85.4K
- X Aug 14 Short interest jumps 31.9% to 112.7K
- X Aug 31 Short interest jumps 75.1% to 197.3K
- X Sep 30 Short interest falls 28.6% to 139.3K
Signal stack
Where each data set points today.
- TrendRANGE
1% above its 50-day average.
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 15, 2026SecBot reports
4 filings · 4 bullish · 0 bearish- BULLISH 6-KJun 8, 2026
Sanofi announced FDA priority review for venglustat NDA to treat type 3 Gaucher disease, with a…
Monitor FDA decision on November 25, 2026, and EU regulatory progress. Positive outcome would open a new revenue stream in rare disease and strengthen Sanofi's lysosomal storage disorder portfolio…
- BULLISH 6-KMay 27, 2026
Sanofi announced positive Phase 2 data for efdoralprin alfa in alpha-1 antitrypsin deficiency…
Positive Phase 2 data for efdoralprin alfa de-risks Sanofi's rare disease pipeline, but near-term stock impact is limited given early stage. Watch for regulatory guidance on Phase 3 or potential…
- BULLISH 6-KApr 27, 2026
Sanofi's 6-K filing reports multiple regulatory catalysts: FDA approval of Dupixent for young…
The cluster of positive regulatory events strengthens Sanofi's immunology and rare disease pipeline, particularly in pediatrics. Monitor the Sarclisa SC FDA decision on July 23, 2026, and the final…
- BULLISH 6-KApr 23, 2026
Sanofi reported strong Q1 2026 results with 13.6% sales growth and 14.0% business EPS growth at…
The strong Q1 performance and guidance affirmation support Sanofi's growth trajectory. The successful integration of recent acquisitions and pipeline progress provide confidence in the company's…
All SNYNF filing & press-release reports (4)
- 6-K reportJun 8, 2026
- 6-K reportMay 27, 2026
- 6-K reportApr 27, 2026
- 6-K reportApr 23, 2026